Ezz Life Science Holdings Ltd. · ASX:EZZ
Ezz Life Science — Investor Presentation (March 2024)
20 slides from Ezz Life Science's investor presentation, Mar 27, 2024
Slide 1: Investor Presentation 1H FY24 and Market Update
Investor Presentation 1H FY24 and Market Update ASX: EZZ
Slide 2: The EZZ Mission
The EZZ Mission Become a leading life science company in Asia- Pacific, improving the quality of life and human health by accelerating innovation to market. ASX: EZZ Investor Presentation 1H FY24 and Market Update 2
Slide 3: Company Highlights
Company Highlights High Demand Omnichannel Improving Products Market Strategy Financials Scientifically formulated products Direct-to-consumer digital strategy Strong financial position and developed for fast-growing continuously optimised through profitable operations enabling consumer markets. str
Slide 4: Capital Structure
Capital Structure Company Profile EZZ Life Sciences Stock Chart (March 2023 to March 2024)** $0.800 1,000,000 Shares on Issue 42,705,000 Share Price $0.52 $0.700 900,000 Market capitalisation ($m) $22.2 800,000 $0.600 52 week High / Low $0.38 - $0.75 700,000 $0.500 Cash Balance (@ 31 Dec) $12.6 600,
Slide 5: Key Personnel
Key Personnel Mark Qin Glenn Cross Ivan Oshry Lily Huang Anthony Guarna CHIEF EXECUTIVE OFFICER NON-EXECUTIVE CHAIRMAN NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR CHIEF FINANCIAL OFFICER Mr Qin is a co-founder of the Mr Cross has 40 years’ experience Mr Oshry has more than 30 years Ms Huang has ov
Slide 6: Company Profile
Company Profile ASX: EZZ Investor Presentation 1H FY24 and Market Update 6
Slide 7: Diverse Product Range
Diverse Product Range We formulate, produce, market and distribute health supplements under the We are an exclusive distributor of skin care products under the EÁORON brand of EZZ. Our deep understanding of our target consumers allows us to brand in Australia and New Zealand to pharmacies, supermark
Slide 8: Our History
Our History 2019 2020 2021 2022 2023 2024 Commenced Became an exclusive Listed on the Australian Launched its store on Launched on multiple Expanded presence on development, distributor of Securities Exchange Douyin, China’s version e-commerce marketplaces in social commerce production and EAORON br
Slide 9: 1H FY24 Highlights
1H FY24 Highlights Strong Financial New Distribution New Product Performance Channels and Development Geographical Markets Strong revenue growth of Eleven new products 43% from $15.1m in 1H Strong growth on the launched under the EZZ FY23 to $21.7m in 1H Douyin and Tmall Global brand and distributed
Slide 10: Development Pipeline
Development Pipeline Deep consumer insights from e- commerce marketplaces drives Data driven to develop development of next generation 5 1 products meeting the needs Data Product products Development of our consumers Analytics Expert in-house sales and 4 marketing capability with a Sales & 2 Highlig
Slide 11: Company Pillars
Company Pillars Life Science Technology Distribution Consumers Product development pipeline Online store and data backed Focus on top-tier distributors Connection to consumers to increasingly feature analytical capabilities enable in target markets with proven through omnichannel healthcare solution
Slide 12: Extensive Distribution Capabilities
Extensive Distribution Capabilities Strong omnichannel marketing capabilities have delivered results Chemists Specialist and Grocery Retailers E-commerce Platforms 600+ 200+ 750+ ASX: EZZ Investor Presentation 1H FY24 and Market Update 12
Slide 13: Recent Recognition
Recent Recognition Frequently #1 among the best- selling nutrition and food Frequently #1 among the most re-ordered children’s products in the last 30 days calcium, iron and zinc products on Douyin in the last 365 days EZZ #41 on the Australian EZZ nominated for the Financial Review’s Fast Global Au
Slide 14: Financials
Financials ASX: EZZ Investor Presentation 1H FY24 and Market Update 14
Slide 15: 1H FY24 Financial Overview
1H FY24 Financial Overview Revenue EBITDA Cash on Hand $21.7M $1.7M $12.6M Up 43% from 1H FY23 Decrease of 7% from 1H FY23 No external debt Gross Margin NPAT Interim Dividend 70%+ $1.1M 1 cent Steady for the period Decrease of 12% from 1H FY23 1H FY24 equating to annualised due to higher marketing s
Slide 16: Operational Financials
Operational Financials Record revenue growth as a result of successful market-driven product development, dynamic channel prioritisation, and targeted B2C marketing Profitability since ASX listing Revenue by Segment 25 21.70 $21.7M 45.6% 9.9% 20 15.13 15.31 $15.1M 15 84.0% 16.0% 11.16 10 90.1% 16.0%
Slide 17: Revenue Mix
Revenue Mix Strong revenue growth across multiple marketplaces and revenue across multiple export markets Revenue by Customer or Platform ($m) Revenue by Geography (FY23) $25 1% 1% $20 $15 26% Australia Greater China $10 New Zealand Others $5 72% $0 2H FY22 1H FY23 2H FY23 1H FY24 HIC Kuaishou Techn
Slide 18: Outlook
Outlook • Cash receipts: Initial investment made into new marketplaces now producing positive cashflows. • Strong revenue growth: Total sales from EZZ’s three main marketplaces are expected to be up more than 75% in 3Q FY24 compared to 3Q FY23. • New products: Three new EZZ products expected to be l
Slide 19: Disclaimer
Disclaimer This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below. This document is not a prospectus, product di
Slide 20: EZZ Life Science Holdings Limited
EZZ Life Science Contact EZZ Life Science Holdings Limited Holdings Limited ABN 83 608 363 604 ASX: EZZ 104 Derby Street, Silverwater NSW 2128 T: 02 9160 2305 E: ir@ezzlife.com.au www.ezzlife.com.au EZZLifescience linkedin.com/company/ezz- EZZAustralia EZZ_Australia life-science-holdings Investor Pr
Ezz Life Science Holdings — Investor Presentation (March 2024) on 6ix